HIV-1 CTL epitope-based DNA vaccine (Pharmexa-Epimmune)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHIV-1 CTL epitope-based DNA vaccine (Pharmexa-Epimmune)
Drug Alias NameHIV DNA vaccine (Pharmexa-Epimmune)EP-1090EPHIV-1090
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBotswanaUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVaxoncoPharmexa-Epimmune
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)Epimmune IncPharmexa-Epimmune
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A